A Chinese medicine composition for preventing or treating ischemic stroke, and its preparation method and use

Abstract

The present invention belongs to the technical field of traditional Chinese medicine, and specifically relates to a traditional Chinese medicine composition for preventing or treating ischemic stroke, and a preparation method and use thereof. The traditional Chinese medicine composition is made of the following raw materials in parts by weight: 1-50 parts of rhododendron root, 1-50 parts of Uncaria rhynchophylla, 1-80 parts of Cyathula capitata, 1-60 parts of Radix Angelicae Pubescentis, 1-50 parts of Radix Puerariae, and 1-10 parts of Radix Notoginseng. The traditional Chinese medicine composition of the present invention has the effects of calming the liver and extinguishing wind, promoting blood circulation, removing blood stasis and dredge channels, and can effectively inhibit inflammatory response, improve blood supply and protect neurons.

Description

Technical Field

[0001] The present invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for preventing or treating ischemic stroke, and a preparation method and use thereof. Background Art

[0002] Stroke is a cerebrovascular disease caused by insufficient blood supply, occlusion, or hemorrhage in the cerebral arteries. Western medicine divides stroke into ischemic stroke and hemorrhagic stroke. The former accounts for approximately 87% of the total and has become the second leading cause of death and the third leading cause of disability worldwide. The incidence and mortality of ischemic stroke are increasing with age. In the past 10 years, the actual number of deaths from ischemic stroke worldwide has increased by 7.7%. The recurrence rate of acute stroke patients in China is as high as 17.7% within one year, and the cumulative recurrence rate over five years exceeds 30%. Currently, the main treatments for ischemic stroke are intravenous thrombolysis and interventional therapy. Some patients will still suffer from a certain degree of sequelae, such as limb paralysis, speech impairment, and swallowing difficulties, which seriously affect their daily lives.

[0003] Ischemic stroke has numerous causes, including intracranial and extracranial arterial stenosis and occlusion, cerebral arterial embolism, hemodynamic factors, hematologic factors, inflammation, infection, lupus erythematosus, Takayasu nodosa, and rheumatoid arthritis. Patients with ischemic stroke may experience transient limb weakness before onset; cerebral infarction may also occur suddenly without any symptoms, followed by a series of symptoms, such as unilateral limb weakness or numbness, unilateral facial numbness or facial paralysis, slurred speech, blurred vision, nausea and vomiting. Current treatment involves surgical thrombolysis in the acute phase, but reperfusion to restore blood flow can lead to severe neurological dysfunction in the short term, resulting in ischemia-reperfusion injury. Western medicine primarily uses rehabilitation training and physical therapy during the recovery phase, but these are costly and time-consuming.

[0004] Traditional Chinese Medicine (TCM) offers unique advantages in preventing or treating the symptoms of ischemic stroke and holds great research potential. TCM believes the fundamental pathogenesis of stroke is an imbalance of yin and yang, with qi and blood flowing upward to the brain. If liver wind, accompanied by phlegm, invades the meridians, causing blood stasis and preventing qi and blood from nourishing the body, symptoms of direct meridian damage manifest as hemiplegia and facial paralysis, without mental disturbance. If wind, yang, phlegm, and fire obscure the mind, causing qi and blood to flow upward to the brain, severe visceral damage manifests as sudden collapse and unconsciousness. The "Clinical Guide to Medical Cases" records that "essence and blood are depleted, water cannot contain wood... Liver yang is hyperactive, and internal wind arises occasionally," indicating that hyperactive liver yang causes internal liver wind. The "Treatise on Blood Symptoms" states that "without blood stasis, new blood cannot be generated... The removal of blood stasis facilitates the generation of new blood, and the generation of new blood naturally dissolves blood stasis," fully demonstrating the dialectical relationship between blood stasis blocking the meridians and new blood production. Therefore, the main treatment principles of nourishing the kidney and calming the liver, and promoting blood circulation and removing blood stasis have gradually been formed in clinical practice. However, clinical practice has found that the efficacy of traditional Chinese medicine compositions designed with the treatment principles of nourishing the kidney and calming the liver, and promoting blood circulation and removing blood stasis alone in preventing or treating ischemic stroke is still poor.

[0005] In view of this, it is also necessary to further explore traditional treatment principles and methods in combination with the pathogenesis of ischemic stroke, and then develop new Chinese medicine compositions that are safer and more effective for preventing or treating ischemic stroke. Summary of the Invention

[0006] The object of the present invention is to provide a traditional Chinese medicine composition with better efficacy for preventing or treating stroke.

[0007] In order to achieve the purpose of the present invention, the present invention adopts the following technical solutions:

[0008] In the first aspect, the present invention provides a traditional Chinese medicine composition for preventing or treating ischemic stroke, wherein the traditional Chinese medicine composition is made of the following raw materials in parts by weight: 1-50 parts of azalea root, 1-50 parts of Uncaria rhynchophylla, 1-80 parts of Cynanchum wilfordii, 1-60 parts of Euphorbia pulex, 1-50 parts of Pueraria root, and 1-10 parts of Panax notoginseng.

[0009] Preferably, in the above-mentioned traditional Chinese medicine composition, the traditional Chinese medicine composition is made of the following raw materials in parts by weight: 15-30 parts of azalea root, 15-30 parts of Uncaria rhynchophylla, 15-60 parts of Cyathula capitata, 20-35 parts of Radix Angelicae Dahuricae, 20-30 parts of Puerariae, and 5-8 parts of Panax notoginseng.

[0010] Preferably, in the above-mentioned traditional Chinese medicine composition, the traditional Chinese medicine composition is made of the following raw materials in parts by weight: 15 parts of azalea root, 15 parts of Uncaria rhynchophylla, 15 parts of Cyperus rotundus, 20 parts of Radix Angelicae Dahuricae, 20 parts of Puerariae lobata, and 5 parts of Panax notoginseng.

[0011] Preferably, in the above-mentioned traditional Chinese medicine composition, the traditional Chinese medicine composition is made of the following raw materials in parts by weight: 30 parts of azalea root, 30 parts of Uncaria rhynchophylla, 60 parts of Cyperus rotundus, 35 parts of Radix Glehniae, 30 parts of Puerariae, and 8 parts of Panax notoginseng.

[0012] In a second aspect, the present invention provides a method for preparing the Chinese medicine composition described in the first aspect above, the preparation method comprising the following steps: weighing each raw material according to the weight parts described in the first aspect above, pre-treating, extracting, and concentrating.

[0013] Preferably, in the above preparation method, the Chinese medicine composition of the present invention can be prepared by conventional methods known in the art.

[0014] Preferably, the extraction methods used in the present invention include but are not limited to decoction extraction, reflux extraction, ultrasonic extraction, supercritical extraction, etc.

[0015] Preferably, the treated API can be extracted using water, an organic solvent commonly used in the art, or a mixture thereof.

[0016] Preferably, the organic solvent is methanol, ethanol, propanol, butanol, ethyl acetate, petroleum ether, etc.

[0017] Preferably, the process includes weighing each raw material drug, crushing, extracting and concentrating.

[0018] Preferably, the extraction method is decoction, and / or the extraction solvent is water or ethanol, and / or the decoction times are 1-3 times, and / or the decoction time each time is 1-3 hours.

[0019] Preferably, aqueous extraction is used (eg, decoction is used).

[0020] In a third aspect, the present invention provides use of the Chinese medicine composition described in the first aspect or the Chinese medicine composition prepared by the preparation method described in the second aspect in preparing medicines.

[0021] Preferably, in the above use, the drug is used to prevent or treat ischemic stroke.

[0022] Preferably, in the above use, the medicine has the effects of calming the liver and extinguishing wind, promoting blood circulation, removing blood stasis and unblocking meridians.

[0023] Preferably, in the above use, the drug can inhibit inflammatory response, improve blood supply, and protect neurons.

[0024] Preferably, in the above use, the drug is in solid form, semi-solid form or liquid form.

[0025] Preferably, in the above use, the medicine is a decoction, decoction, powder, oral liquid, paste, granule, tablet or capsule.

[0026] Preferably, in the above use, the medicine is a decoction or granules.

[0027] The formula of the Chinese medicine composition of the present invention is as follows:

[0028] The main clinical manifestations of ischemic stroke include sudden collapse, unconsciousness, hemiplegia, facial paralysis, and slurred speech. Milder cases may only present with vertigo, hemiplegia, facial paralysis, and hemiplegia. Ischemic stroke falls under the category of emotional disorders in Traditional Chinese Medicine, similar to "stroke." The pathogenesis is primarily due to hyperactivity of liver yang, internal liver wind, and disordered qi and blood, which invade the brain. This leads to blood stasis in the brain vessels, resulting in irregular blood circulation and the aforementioned symptoms. Traditional prescriptions focus on nourishing the kidneys and calming the liver, promoting blood circulation and removing blood stasis, but their effectiveness in clinical prevention and treatment still needs to be improved.

[0029] Therefore, this prescription is based on calming the liver and extinguishing wind, promoting blood circulation, removing blood stasis, and unblocking the meridians. Rhododendron root and blood stasis are the main herbs, which stop bleeding, reduce swelling, and relieve pain. Scutellaria baicalensis, Panax notoginseng, and Radix Glechomae are auxiliary herbs, promoting blood circulation, removing blood stasis, and unblocking the meridians. Uncaria rhynchophylla is used to calm the liver and extinguish wind, relieve spasms, and is the adjuvant. Pueraria root is used to guide the herbs upward to the top of the head. In summary, the entire prescription can calm the liver and extinguish wind, promote blood circulation, remove blood stasis, and unblock the meridians, thereby inhibiting inflammation, improving blood supply, and protecting neurons.

[0030] Azalea root is the root of the Ericaceae plant. It has a sour, sweet, and warm nature. It harmonizes blood and stops bleeding, reduces swelling, and relieves pain. It is used to treat irregular menstruation, hematemesis, epistaxis, bloody stools, metrorrhagia, dysentery, abdominal pain, rheumatic pain, and traumatic injuries.

[0031] Uncaria rhynchophylla refers to the dried, hooked stems and branches of Uncaria rhynchophylla, Uncaria macrophylla, Uncaria tomentosa, Uncaria sinensis, or Uncaria sessile fruit, all of the Rubiaceae family. It is sweet and cool. It calms wind and quells convulsions, clears heat and soothes the liver. It is used for internal liver wind disturbances, epilepsy and convulsions, high fever seizures, colds and convulsions, crying in children, eclampsia during pregnancy, and headaches and dizziness.

[0032] Chuanposhi (Chuanposhi) is the root of the mulberry tree (Zhushu), also known as the Cudrania tricuspidata plant. It has a slightly bitter, cooling flavor. It dispels wind and dampness, promotes blood circulation and unblocks menstruation. It treats rheumatic joint pain, jaundice, stranguria, swelling, amenorrhea, hemoptysis due to overuse, injuries from falls, and carbuncles and boils.

[0033] "Ghost Arrow Feather" refers to the winged branches or wing-like appendages of the Euonymus japonicus plant (Euonymus spp.), a plant of the Euonymus family. It has a bitter and pungent flavor and a cold nature. It is used to treat masses, abdominal pain, amenorrhea, dysmenorrhea, metrorrhagia, postpartum abdominal pain due to blood stasis, retained lochia, hernia, pain in the joints, sores, bruises, abdominal pain caused by insect infestation, burns, and snake bites.

[0034] Pueraria root (kudzu root) is the dried root of the leguminous plant Pueraria lobata, commonly known as wild kudzu. It has a sweet, pungent, and cooling flavor. It is used for exogenous fever, headache, stiff neck and back pain, thirst, polydipsia, persistent measles, dysentery, diarrhea, dizziness, headache, hemiplegia caused by stroke, chest pain, and alcohol poisoning.

[0035] Raw Sanqi is the dried root of the Araliaceae plant Panax notoginseng. It has a sweet, slightly bitter, and warming flavor. It is used for hemoptysis, hematemesis, epistaxis, bloody stool, metrorrhagia, bleeding from trauma, stabbing pain in the chest and abdomen, and swelling and pain from falls.

[0036] The present invention has the following beneficial effects:

[0037] (1) The Chinese medicine composition of the present invention further optimizes the compatibility based on the traditional treatment principle of "nourishing the kidney and calming the liver, promoting blood circulation and removing blood stasis" for ischemic stroke, and adopts the treatment method of calming the liver and extinguishing wind, promoting blood circulation and stopping bleeding, and removing blood stasis and unblocking meridians, which significantly enhances the effect of the Chinese medicine composition in preventing or treating ischemic stroke.

[0038] (2) The Chinese medicine composition of the present invention has the effects of inhibiting inflammatory response, improving blood supply and protecting neurons. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 : Representative photos of the effects of the Chinese herbal composition of the present invention on rat hippocampal tissue damage (magnification X0.7 and X20.9).

[0040] Figure 2 : Representative photos of the effects of the Chinese herbal composition of the present invention on rat hippocampal neurons (magnifications X2 and X20). DETAILED DESCRIPTION

[0041] The present invention will be further described below with reference to specific embodiments. It should be understood that the specific embodiments described herein are only used to illustrate the present invention and are not intended to limit the scope of the present invention.

[0042] If no specific techniques or conditions are specified in the examples, the experiments were carried out according to the techniques or conditions described in the literature in the field or according to the product instructions. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0043] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are commercially available products unless otherwise specified.

[0044] Preparation Example: Example 1

[0045] 15g of azalea root, 15g of Uncaria rhynchophylla, 15g of Cyathula capitata, 20g of Psoralea corylifolia, 20g of Pueraria root, and 5g of raw Panax notoginseng.

[0046] Total weight: 90g

[0047] All the raw materials were crushed into fine powder, decocted with 1000 mL of distilled water, and filtered after 1.5 hours of first decoction to obtain a primary filtrate. The residue was decocted with 1000 mL of distilled water for another 1.5 hours, and filtered to obtain a secondary filtrate. The primary and secondary filtrates were combined and concentrated under reduced pressure to obtain 300 mL of concentrated solution. Example 2

[0048] 30g of azalea root, 30g of Uncaria rhynchophylla, 60g of Cyathula capitata, 35g of Psoralea corylifolia, 30g of Pueraria root, and 8g of raw Panax notoginseng.

[0049] Total weight: 193g

[0050] The preparation method is the same as that of Example 1.

[0051] Comparative Example 1:

[0052] 15g of azalea root, 15g of Uncaria rhynchophylla, 15g of Ligusticum chuanxiong, 20g of Psoralea corylifolia, 20g of Pueraria root, and 5g of raw Panax notoginseng.

[0053] Total weight: 90g

[0054] Comparative Example 2:

[0055] Uncaria rhynchophylla 30g, Pueraria root 40g, raw Panax notoginseng 20g.

[0056] Total weight: 90g

[0057] The preparation method is the same as that of Example 1.

[0058] Positive drug group:

[0059] Naodesheng Pills: Purchased from Hunan Tianji Caotang Pharmaceutical Co., Ltd. (National Medicine Approval No. Z20153028). Naodesheng Pills were dissolved in normal saline and the oral gavage dosage for SD rats was calculated based on the adult dosage of 6 pills per day.

[0060] Effect Example: Pharmacodynamic Study on the Chinese Medicine Composition of the Present Invention for Preventing or Treating Ischemic Stroke

[0061] 1. Preparation for establishing an ischemic stroke animal model:

[0062] SPF-free male Sprague-Dawley rats, 6–8 weeks old, weighing (160 ± 10) g, were purchased from Beijing Weitonglihua Laboratory Animal Technology Co., Ltd. (Animal Production License No. SCXK (Beijing) 2016-0011). They were housed at the Animal Experiment Center of Beijing Liaoweiyuan Pharmaceutical Technology Co., Ltd. (Animal Production License No. SYXK (Beijing) 2022-0007) at a temperature of (22 ± 2)°C, a humidity of (50 ± 10)%, and a 12-h light / dark cycle. Animals had free access to food and water.

[0063] 2. Animal Modeling, Grouping, and Dosing

[0064] After 7 days of adaptive feeding, the experimental animals were weighed. All groups, except the control group, were surgically induced into a cerebral ischemic model using middle cerebral artery occlusion (MCAO). Food and water were withheld for 12 hours before surgery. The specific procedure was as follows: Before the experiment, the nylon suture was cleaned with 75% alcohol, marked 18.5 mm from the ball end, and placed in 0.9% sterile saline. Rats were weighed, anesthetized with an intramuscular injection of 75 mg / kg of Zolpidem 50 (tirazole), and secured in a supine position on the operating table. A constant temperature pad and heat lamp were used to maintain warmth throughout the surgery. The rat's neck was shaved, and the skin was incised midway through the neck. The left common carotid artery (CCA), external carotid artery (ECA), and internal carotid artery (ICA) were isolated sequentially. Sutures were ligated to block blood flow in each of the CCA and ECA, and the ICA was clamped with a vascular clip. A 0.2 mm incision was made in the ECA, and 0.1 mL of 60 μL of sodium heparin in saline was injected using a syringe (the ICA artery clamp was released during the injection and re-clamped after the injection). The distal end of the CCA was then incised, and a sterile, custom-made suture (0.25 mm diameter, 0.32 mm ball diameter) was inserted and gently tied with surgical suture. The ICA artery clamp was immediately released, and the tail of the suture was gently pushed through the common carotid bifurcation and along the ICA into the skull, extending approximately 18.5 ± 0.5 mm to block blood flow from the MCA and intracranial reflux, thus creating a suture embolization model. Sprinkle a small amount of penicillin powder over the surgical suture site. Depending on the rat's condition, administer 1-2 mL of normal saline intraperitoneally to replenish intraoperative fluid loss. Maintain the rat in a single cage in a constant-temperature room postoperatively. This procedure typically takes 10-15 minutes. After surgery, administer intramuscular penicillin at a rate of 10,000 units per rat per day for four consecutive days. Place the rat in a clean IVC cage, place a trifold surgical paper under the rat, and continue observation until the rat awakens naturally. Once awake, the rat can eat and drink freely.

[0065] After modeling, SD rats were randomly divided into 6 groups: Example 1, Example 2, Comparative Example 1, Comparative Example 2, model group, and positive drug group, with 14 rats in each group. Fourteen untreated SD rats were also selected as a normal control group. The Example 1, Example 2, Comparative Example 1, and Comparative Example 2 groups were administered with the concentrate prepared in the "Preparation Example" section above, at an intragastric dose of 1.6 mL / rat / day to ensure consistency between groups.

[0066] The control group and the model group were gavaged with 1.6 mL / animal / day of normal saline.

[0067] The drug was administered orally once a day for 21 consecutive days.

[0068] Positive drug group: Naodesheng pills were dissolved in 500 mL of normal saline and administered to SD rats via oral gavage at a dose of 1.6 mL / rat / day, calculated based on the daily intake of 6 pills for adults.

[0069] The dosage is based on the clinically recommended daily oral dosage for a 70 kg adult and is converted to a rat oral dosage using the body surface area conversion factor for adults and rats. For dosage calculation methods, see, for example, Xu Shuyun, Pharmacological Experimental Methodology. Anhui Medical University, Anhui Province, January 1, 2002; Zhao Wei, Sun Guozhi. Conversion of Doses between Different Species of Experimental Animals [J]. Animal Husbandry and Veterinary Science and Technology Information, 2010(05):52-53.

[0070] 3. Tissue Sample Collection

[0071] After the final dose, the rats were fasted but not watered for 12 hours. SD rats were anesthetized with an intraperitoneal injection of 2% pentobarbital. Blood was collected from the abdominal aorta and placed in anticoagulant tubes. The rats were refrigerated at 4°C for 2 hours and then centrifuged. The upper plasma layer was collected and stored frozen at -20°C. After blood was collected from the abdominal aorta, the rats were guillotined, the scalp was cut, the skull was opened, the brain was removed, the olfactory bulbs were removed, and the left and right hemispheres were separated. The brain was then transferred to liquid nitrogen and the left ischemic brain was ground into powder and stored frozen at -80°C. After the rats were anesthetized, the chest cavity was opened to expose the heart. The rats were perfused with a needle until their limbs turned white and stiff. The rats were then guillotined, the intact brain removed, immersed in 4% paraformaldehyde, and subsequently embedded in paraffin.

[0072] 4. Effect Index Test

[0073] (1) ELISA method to detect serum inflammatory factor levels

[0074] The levels of transforming growth factor-β (TGF-β), interleukin-8 (IL-8), and tumor necrosis factor-α (TNF-α) in the serum of SD rats were detected according to the ELISA kit instructions.

[0075] (2) Detection of serum VEGF and VEGFR2 levels by ELISA

[0076] The levels of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor 2 (VEGFR2) in the serum of SD rats were detected according to the instructions of the ELISA kit.

[0077] (3) Immunofluorescence staining method to detect brain damage

[0078] Brain tissue was fixed with 4% paraformaldehyde solution, embedded in paraffin, and then sectioned (5 μm thickness). The sections were then baked for 1 h, dewaxed in xylene, dehydrated with graded alcohols, stained with conventional hematoxylin-eosin, transparentized with xylene, and mounted with neutral resin. The pathological morphology of the ischemic area of ​​the brain tissue was observed under an optical microscope and photographed.

[0079] (4) Nissl staining method to detect necrotic neurons

[0080] The preserved brain tissue was paraffin-embedded and 5 μm thick paraffin sections were prepared. After dewaxing, the sections were Nissl-stained for 30 min, washed with deionized water, dehydrated with anhydrous ethanol, transparentized with xylene, and mounted with neutral resin. The neurons were observed under a microscope.

[0081] 5. Statistical Methods

[0082] GraphPad Prism 8.0 was used for statistical analysis and plotting. One-Way ANOVA was used to compare the means among multiple groups, and P < 0.05 indicated statistically significant differences.

[0083] 6. Results

[0084] (1) Levels of inflammatory factors

[0085] The stroke process is closely related to neuroinflammation. The mechanism of neuroinflammation is primarily the activation of microglia and astrocytes, which then produce proinflammatory cytokines (IL-8, TNF-α, and TGF-β). The inflammatory response promotes neuronal damage through various signaling pathways, leading to cell death and worsening ischemic stroke. ELISA results showed that compared to the model group, Examples 1 and 2 significantly reduced the levels of the inflammatory factors IL-8, TNF-α, and TGF-β, inhibiting the inflammatory response. This helps suppress the inflammatory storm during stroke and mitigates disease progression. The results are shown in Table 1.

[0086] Table 1: Expression levels of inflammatory factors in SD rat serum ( , n=4)

[0087]

[0088] Compared with the control group, P < 0.05; △ Compared with the model group, P < 0.05

[0089] (2) VEGF and VEGFR2 expression levels

[0090] VEGF / VEGFR2 is one of the most important pathways regulating angiogenesis. VEGF has a very high affinity for endothelial cells, promoting their proliferation and forming branched blood vessels, enhancing vascular permeability, and restoring blood flow to ischemic and hypoxic brain tissue. Simultaneously, it upregulates VEGFR2 levels, leading to continuous angiogenesis and, in turn, saving neurons damaged by cerebral ischemia. ELISA results showed that both Examples 1 and 2 significantly increased the expression levels of VEGF and VEGFR2, promoting angiogenesis and saving damaged neurons. The results are shown in Table 2.

[0091] Table 2: Serum VEGF and VEGFR2 expression levels in SD rats ( , n=4)

[0092]

[0093] Compared with the control group, P < 0.05; △ Compared with the model group, P < 0.05

[0094] (3) Brain damage

[0095] The results of immunofluorescence staining suggest that the model group showed a large number of neuronal necrosis, dissolution or calcification in the hippocampus and thalamus, with loose structure, neovascularization, and infiltration of a large number of macrophages and lymphocytes. Brown-yellow granules were visible in the cytoplasm of macrophages. In the Example 1 group, the number of neurons in the hippocampus and thalamus was abundant and tightly arranged, with normal neuronal morphology and structure, clear nuclear cytoplasmic demarcation, obvious nucleoli, and no obvious inflammation. In the Example 2 group, the number of neurons in the hippocampus was slightly reduced, accompanied by a small amount of neovascularization; no obvious pathological changes were seen in the thalamus. In the comparative example 1 group, punctate neuronal necrosis and dissolution were seen in the thalamus, accompanied by infiltration of macrophages and a small amount of lymphocytes, and brown-yellow granules were seen in the cytoplasm of macrophages; a small number of neurons were seen in the CA3 region of the hippocampus, with darker cell staining and unclear nuclear cytoplasmic demarcation. In the comparative example 2 group, the number of neurons in the hippocampus was reduced, neovascularization was seen, and infiltration of macrophages and a small amount of lymphocytes was seen; a small number of calcifications were seen in the thalamus. In summary, it is shown that Example 1 and Example 2 can reduce brain damage and inflammatory response, and inhibit the infiltration of macrophages and lymphocytes. Figure 1 shown.

[0096] (4) Neuronal cells

[0097] Neuronal cells play an important role in the occurrence and development of ischemic stroke. The results of Nissl staining indicate that the morphology of the neurons in the CA1 region of the hippocampus on the ischemic side of the model group is mostly vacuolar, with unclear nucleoli, a reduced number of Nissl bodies, and a reduced number of neurons with positive Nissl staining. In Example 1, the neuronal cell structure in the CA1 region of the hippocampus is relatively complete, the nuclei are mostly round, the nucleoli are clear, the cytoplasm is darkly stained, and neuronal damage is significantly reduced. In Example 2, the neuronal cell structure in the CA1 region of the hippocampus is relatively complete, the nuclear structure is normal, and the number of Nissl bodies is slightly reduced. In the comparison example 1 group, the neuronal cell morphology of CA1 is vacuolar, with unclear nucleoli. In the comparison example 2 group, the cell structure is incomplete, the neurons in the CA1 region of the hippocampus are damaged, and the number of Nissl bodies is reduced. In summary, the results of Nissl staining indicate that Examples 1 and 2 can reduce the shrinkage, damage and death of neuronal cells. The results are as follows Figure 2 shown.

[0098] Obviously, those skilled in the art may make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if such changes and modifications fall within the scope of the claims and their equivalents, the present invention is intended to include such changes and modifications.

Claims

1. A Chinese medicine composition for preventing or treating ischemic stroke, Features: The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 1-50 parts of azalea root, 1-50 parts of Uncaria rhynchophylla, 1-80 parts of Cyathula capitata, 1-60 parts of Psoralea corylifolia, 1-50 parts of Pueraria root, and 1-10 parts of raw Panax notoginseng.

2. The Chinese medicine composition according to claim 1, Features: The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15-30 parts of rhododendron root, 15-30 parts of Uncaria rhynchophylla, 15-60 parts of Cyathula capitata, 20-35 parts of Psoralea corylifolia, 20-30 parts of Pueraria root and 5-8 parts of raw Panax notoginseng.

3. The Chinese medicine composition according to claim 2, Features: The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15 parts of rhododendron root, 15 parts of Uncaria rhynchophylla, 15 parts of Cyathula capitata, 20 parts of Psoralea corylifolia, 20 parts of Pueraria root and 5 parts of raw Panax notoginseng.

4. The Chinese medicine composition according to claim 2, Features: The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 30 parts of rhododendron root, 30 parts of Uncaria rhynchophylla, 60 parts of Cyathula capitata, 35 parts of Psoralea corylifolia, 30 parts of Pueraria root and 8 parts of raw Panax notoginseng.

5. A method for preparing the Chinese medicine composition according to any one of claims 1 to 4, Features: The preparation method comprises the following steps: weighing each raw material drug according to the weight proportions described in any one of claims 1 to 4, pre-treating, extracting, and concentrating.

6. Use of the Chinese medicine composition according to any one of claims 1 to 4 or the Chinese medicine composition prepared by the preparation method according to claim 5 in the preparation of a medicament for preventing or treating ischemic stroke.

7. The use according to claim 6, Features: The drug is in solid form, semi-solid form or liquid form.

8. The use according to claim 7, Features: The medicine is in the form of decoction, powder, oral liquid, paste, granules, tablets or capsules.

9. The use according to claim 8, Features: The medicine is in the form of decoction or granules.

Images